Rushab Choksi

546 total citations
13 papers, 278 citations indexed

About

Rushab Choksi is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, Rushab Choksi has authored 13 papers receiving a total of 278 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Endocrinology, Diabetes and Metabolism, 5 papers in Surgery and 5 papers in Molecular Biology. Recurrent topics in Rushab Choksi's work include Diabetes Treatment and Management (7 papers), Metabolism, Diabetes, and Cancer (5 papers) and Lipoproteins and Cardiovascular Health (4 papers). Rushab Choksi is often cited by papers focused on Diabetes Treatment and Management (7 papers), Metabolism, Diabetes, and Cancer (5 papers) and Lipoproteins and Cardiovascular Health (4 papers). Rushab Choksi collaborates with scholars based in United States and Antigua and Barbuda. Rushab Choksi's co-authors include Benjamin J Epstein, David Sutton, Rebecca F. Goldfaden, Jessica Reid, Jennifer Hardy, Todd Lewis, Mae Sheikh‐Ali, Steven M. Smith, Edward Pereira and Mohannad Bisharat and has published in prestigious journals such as PLoS ONE, Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy and Diabetes Metabolic Syndrome and Obesity.

In The Last Decade

Rushab Choksi

13 papers receiving 273 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rushab Choksi United States 8 169 133 108 38 37 13 278
Yingqiong Peng China 4 188 1.1× 127 1.0× 95 0.9× 30 0.8× 19 0.5× 4 278
Xue‐Nan Sun China 9 93 0.6× 71 0.5× 97 0.9× 31 0.8× 44 1.2× 14 251
Miriam Kozárová Slovakia 9 179 1.1× 156 1.2× 120 1.1× 15 0.4× 33 0.9× 25 274
Ghazaleh Behnammanesh United States 9 146 0.9× 84 0.6× 116 1.1× 29 0.8× 64 1.7× 11 321
Angélique Arcambal France 6 161 1.0× 74 0.6× 86 0.8× 22 0.6× 61 1.6× 9 319
Naoki Itabashi Japan 7 202 1.2× 87 0.7× 104 1.0× 32 0.8× 112 3.0× 18 328
Anika Götz Germany 9 145 0.9× 66 0.5× 93 0.9× 36 0.9× 137 3.7× 9 395
Marie‐Claude Brulhart‐Meynet Switzerland 10 72 0.4× 59 0.4× 92 0.9× 46 1.2× 49 1.3× 16 343
F. Ciani Italy 13 72 0.4× 82 0.6× 122 1.1× 26 0.7× 45 1.2× 24 361
F. Sato Japan 7 115 0.7× 183 1.4× 109 1.0× 20 0.5× 40 1.1× 9 361

Countries citing papers authored by Rushab Choksi

Since Specialization
Citations

This map shows the geographic impact of Rushab Choksi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rushab Choksi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rushab Choksi more than expected).

Fields of papers citing papers by Rushab Choksi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rushab Choksi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rushab Choksi. The network helps show where Rushab Choksi may publish in the future.

Co-authorship network of co-authors of Rushab Choksi

This figure shows the co-authorship network connecting the top 25 collaborators of Rushab Choksi. A scholar is included among the top collaborators of Rushab Choksi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rushab Choksi. Rushab Choksi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Penn, Marc S., Calum A. MacRae, Rebecca F. Goldfaden, et al.. (2023). Association of chronic neutrophil activation with risk of mortality. PLoS ONE. 18(7). e0288712–e0288712. 1 indexed citations
2.
Hardy, Jennifer, Rebecca F. Goldfaden, David Sutton, et al.. (2022). Danuglipron. Glucagon-like peptide 1 receptor agonist, Treatment of type 2 diabetes, Treatment of obesity. Drugs of the Future. 47(6). 407–418. 1 indexed citations
3.
Hardy, Jennifer, et al.. (2021). A Review of the Clinical Pharmacology of Pelacarsen: A Lipoprotein(a)-Lowering Agent. American Journal of Cardiovascular Drugs. 22(1). 47–54. 19 indexed citations
4.
Hardy, Jennifer, Edward Pereira, Todd Lewis, et al.. (2021). A Critical Review of the Efficacy and Safety of Inclisiran. American Journal of Cardiovascular Drugs. 21(6). 629–642. 32 indexed citations
5.
Hardy, Jennifer, Rebecca F. Goldfaden, Jessica Reid, et al.. (2021). A Review on the Efficacy and Safety of Oral Semaglutide. Drugs in R&D. 21(2). 133–148. 19 indexed citations
6.
Reid, Jessica, et al.. (2020). Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors for Cardiovascular Disease Prevention. American Journal of Cardiovascular Drugs. 20(5). 419–429. 2 indexed citations
7.
Reid, Jessica, et al.. (2020). A Review of the Efficacy and Tolerability of Bempedoic Acid in the Treatment of Hypercholesterolemia. American Journal of Cardiovascular Drugs. 20(6). 535–548. 23 indexed citations
8.
Reid, Jessica, et al.. (2019). <p>A spotlight on alirocumab in high cardiovascular risk patients with type 2 diabetes and mixed dyslipidemia: a review on the emerging data</p>. Diabetes Metabolic Syndrome and Obesity. Volume 12. 1897–1911. 7 indexed citations
9.
Reid, Jessica, et al.. (2019). Efpeglenatide. Glucagon-like peptide 1 (GLP-1) receptor agonist, Treatment for type 2 diabetes. Drugs of the Future. 44(6). 435–435. 3 indexed citations
10.
Choksi, Rushab, et al.. (2014). Tofogliflozin: A highly selective SGLT2 inhibitor for the treatmentof type 2 diabetes. Drugs of today. 50(11). 739–739. 15 indexed citations
11.
Epstein, Benjamin J, et al.. (2013). SGLT-2 inhibitors and their potential in the treatment of diabetes. Diabetes Metabolic Syndrome and Obesity. 6. 453–453. 86 indexed citations
12.
Choksi, Rushab, et al.. (2012). Dapagliflozin: A Novel Sodium‐Glucose Cotransporter Type 2 Inhibitor for the Treatment of Type 2 Diabetes Mellitus. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 32(1). 80–94. 48 indexed citations
13.
Epstein, Benjamin J, Steven M. Smith, & Rushab Choksi. (2009). Recent changes in the landscape of combination RAS blockade. Expert Review of Cardiovascular Therapy. 7(11). 1373–1384. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yingqiong Peng Breakdown of academic impact, for papers by Xue‐Nan Sun Breakdown of academic impact, for papers by Miriam Kozárová Breakdown of academic impact, for papers by Ghazaleh Behnammanesh Breakdown of academic impact, for papers by Angélique Arcambal Breakdown of academic impact, for papers by Naoki Itabashi Breakdown of academic impact, for papers by Anika Götz Breakdown of academic impact, for papers by Marie‐Claude Brulhart‐Meynet Breakdown of academic impact, for papers by F. Ciani Breakdown of academic impact, for papers by F. Sato
Rankless by CCL
2026